FDA Approves ROCURONIUM — Fresenius Kabi USA, LLC

Fresenius Kabi USA, LLC announced on June 9 a new FDA approval for rocuronium bromide, potentially revitalizing the generic neuromuscular blockers market by strengthening competition in the widely used intravenous brand. This entry could prompt pricing adjustments and drive market share gains as healthcare providers seek cost-effective alternatives to existing labeled products.